Consumer Portfolio Services, Inc. increased its revolving credit facility with Capital One from $390 million to $518 million to fund growing loan originations. This upsizing raises the company's total credit capacity above $1 billion for the first time, supporting expansion in its auto loan portfolio. The loans are secured by automobile receivables, and the facility extends through October 2027 with an option for amortization afterward. This move reflects strong demand in CPS's dealership network and positions the company for continued growth in lending programs.
Consumer Portfolio Services' credit facility upsizing is presented here with Pluang's Financials sector market data as of Oct 13, 2026 20:51 WIB. Of 118 priced Financials-sector US stocks tradable on Pluang, 59 rose and 57 fell today. Notable movers include BTBT at USD 1.21 with a 1-day change of -2.42%, BX at USD 112.18 down 2.26%, and PURR at USD 10.17 down 2.21%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
